Market Overview

UPDATE: Citigroup Upgrades Regeneron Pharmaceuticals

Related REGN
UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following Good Results Of Drug Study
Benzinga's Top #PreMarket Gainers

On Monday, Citigroup upgraded shares of Regeneron (NASDAQ: REGN) from Neutral to Buy and raised the price target from $342 to $390. Analyst Yaron Werber does not “anticipate finding a better entry point near term.”

In the note, Werber cited an in-house survey of retinal surgeons which “suggests Eylea will beat ests near/long term due to solid demand in [diabetic macular edema].”

Regeneron's pipeline is full of “value that is still not being priced into the stock,” said the analyst. Werber sees revenues of $850M, $230M, $137M, and $530M from alirocumab, sarilumab, dupilumab in AD, and dupilumab in asthma respectively. Werber's $390 price target is based on “30x 2015E EPS of $12.99.”

Shares of Regeneron are up 1.43 percent to $334.20 in Monday's pre-market trading. The analyst's price target is 16.5 percent above current levels.

Posted-In: CitigroupAnalyst Color Analyst Ratings


Most Popular

Related Articles (REGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free